CBiPS1sv-4F-40

General

Cell Line

hPSCreg name ESi007-A
Cite as:
ESi007-A (RRID:CVCL_V189)
Alternative name(s)
CBiPS1sv-4F-40
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 13th April 2022
Notes Please note that the correct synonym is "CBiPS1sv-4F-40", not "CBiPSsv-4F-40" as stated in PMID:30778227. [NM]
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Spanish Stem Cell Bank (ES)
Contact:
Inbiomed
Owner Inbiomed
Distributors
Derivation country Spain

External Databases

BioSamples SAMEA3303231
Cellosaurus CVCL_V189
EBiSC ESi007-A
Wikidata Q54808661

General Information

Publications
Projects
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Additional restrictions:

available for research use, but only with the approvals from the competent authority (specific to each country).

Donor Information

General Donor Information

Sex female
Age of donor (at collection) neonate

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.

External Databases (Donor)

BioSamples SAMEA3303248

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Provide contact information of the holder of the original Donor Information Sheet: Alessandra Giorgetti
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? No
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? Yes
Details on restriction to research project Under the Law 14/2007, of 3rd July, on Biomedical Research and the Royal Decree 1527/2010 of November 15th
Does consent permit unforeseen future research, without further consent? No
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? Yes
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? Yes
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? No
a public organisation? No
a non-profit company? No
a for-profit corporation? Yes
Does consent expressly permit collection of genetic information? Yes
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
How may genetic information associated with the cell line be accessed? No information
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? Yes
Does consent permit access to medical records of the donor? No
Does consent permit access to any other source of information about the clinical treatment or health of the donor? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Ethics Committee Center of Regenerative Medicine in Barcelona
Approval number
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Ethics Committee Center of Regenerative Medicine in Barcelona
Approval number
Do you have obligations to third parties in regard to the use of the cell line? No
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
Any hematopoietic stem cell that is part of a umbilical cord blood.
Source cell origin
Blood that remains in the placenta and in the attached umbilical cord after childbirth[WP].; Cord blood is collected because it contains stem cells, which can be used to treat hematopoietic and genetic disorders.[WP]
Synonyms
  • cord blood
  • fetal blood
  • umbilical cord blood
Source cell type (free text) Cord blood CD133+
Age of donor (at collection) neonate

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Other

Selection criteria for clones morphological
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Gelatin
Feeder cells Mouse embryonic fibroblasts
Cellfinder Ont Id: EFO_0004040
Passage method Mechanically
CO2 Concentration 5 %
Medium Other medium:
Base medium: Knockout DMEM
Main protein source: Knock-out serum replacement
Serum concentration: 20 %
Supplements
NEAA 1 %
Glutamax 2 mM
2-mercaptoethanol 0,05 %
bFGF 10 ng/ml
Penicillin Streptomycin 0,5 %

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
Alkaline Phosphatase
Yes
NANOG
Yes
POU5F1 (OCT-4)
Yes
SSEA-3
Yes
TRA 1-60
Yes
ZFP42 (REX-1)
Yes
SOX2
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
In vitro spontaneous differentiation
Marker Expressed
FOXA2
Yes
AFP
Yes
SOX17
Yes
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
In vitro spontaneous differentiation
Marker Expressed
SMA
Yes
MEOX
Yes
AAP
Yes
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma
In vitro spontaneous differentiation
Marker Expressed
Tuj1
Yes
PAX6
Yes
NeuroD3
Yes
Sox1
Yes

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Certificate of Analysis

Is there a certificate of analysis available?
Yes
Passage: 23

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Is there genome-wide genotyping or functional data available?
Yes